MoneyWorks4Me

Lupin informs about press release

05 Jan 2023 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it enclosed a Press Release as regards launch of a novel fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients under the brand name DIFIZMA® in India.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1753.40
Dr. Reddys Labs. 1316.00
Cipla 1358.70
Lupin 1954.35
Zydus Lifesciences 1167.65
View more..